Vaccine Efficacy Trials

Surrogate endpoints in HIV vaccine studies discussed

Published in AIDS Weekly, May 26th, 2003

A group of researchers from several institutions have proposed two surrogate endpoints for HIV vaccine efficacy trials: pre-antitretroviral therapy (ART) viral load trajectories and a composite endpoint defined as either virologic failure (above a threshold) or ART initiation.

P. Gilbert, of the Fred Hutchinson Cancer Research Center, presented the team's arguments at the 10th Conference on Retroviruses and Opportunistic Infections, held in Boston, Massachusetts, earlier in 2003.

"Initial HIV vaccines are unlikely to prevent acquisition of HIV in all recipients. Moreover, several current vaccines are designed to reduce viremia post-acquisition of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry